Fig. 4: scRNA-seq analysis from PBMC samples at the baseline and at irAEs onset from three patients with irAEs and at the baseline and second to fifth infusion in three patients without any irAEs and response to immunotherapy.
a, UMAP plot, with overview of the main immune cell types for the above-mentioned conditions (n = 6 patients). A total of 118,734 PBMCs were sequenced. NK, natural killer b, Dot plot with the average expression of the significantly differentially expressed cytokines and chemokines from the multiplex MSD assay in the main immune cell types in the scRNA-seq analysis at the two time points (TP0 and TP1) for the six patients. The size of the dot represents the percentage of cells that show expression and the color of the dot represents the average expression. c,d, UMAP for CXCL9 for TP0 and TP1 in patients with and without irAEs (n = 6) (c) and violin plot for the CXCL9 signal in main cell types for TP0 and TP1 in patients with and without irAEs (n = 6) (d). e,f, UMAP for CXCL10 for TP0 and TP1 in patients with and without irAEs (n = 6) (e) and violin plot for the CXCL10 signal in main cell types for TP0 and TP1 in patients with and without irAEs (n = 6) (f). g,h, UMAP for IFNγ for TP0 and TP1 in patients with and without irAEs (n = 6) (g) and violin plot for the IFNγ signal in main cell types for TP0 and TP1 in patients with and without irAEs (n = 6) (h). i,j, UMAP for IL-10 for TP0 and TP1 in patients with and without irAEs (n = 6) (i) and violin plot for the IL-10 signal in main cell types for TP0 and TP1 in patients with and without irAEs (n = 6) (j). k,l, UMAP for IL-12A for TP0 and TP1 in patients with and without irAEs (n = 6) (k) and violin plot for the IL-12A signal in main cell types for TP0 and TP1 in patients with and without irAEs (n = 6) (l). m,n, UMAP for IL-21 for TP0 and TP1 in patients with and without irAEs (n = 6) (m) and violin plot for the IL-21 signal in main cell types for TP0 and TP1 in patients with and without irAEs (n = 6) (n).
